X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Why won’t the insurance industry tell the truth about medicine costs?

By Robert Zirkelbach  |    May 10, 2017
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care...   Read More

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

By Holly Campbell  |    May 4, 2017
We have seen a deluge of data recently from government actuaries and pharmacy benefit managers showing a dramatic slowdown in medicine spending growth. And the QuintilesIMS Medicines Use and...   Read More

New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price

By Holly Campbell  |    March 29, 2017
More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of...   Read More

How innovative medicines are benefiting countries across the globe

By Mark Grayson  |    March 1, 2017
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing...   Read More

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    February 17, 2017
Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates,...   Read More

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

By Stephen J. Ubl  |    January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...   Read More

Medicare Monday: New research finds trends in Average Sales Price of Part B drugs remains stable

By Kelsey Lang  |    December 19, 2016
Earlier this year, we looked at Average Sales Price (ASP) and how it works in Medicare Part B. As you may remember, ASP (the method for reimbursing drugs covered by Part B) is a market-based price...   Read More

Are insurers exaggerating medicine costs to justify premium increases? Consumers think so.

By Robert Zirkelbach  |    September 9, 2016
Despite recent headlines, U.S. spending on prescription medicines continues to decline. In fact, new data from Altarum Institute found that spending on prescription medicines grew by just 3.9...   Read More

Study finds actual cost of 14 new medicines is billions less than predicted

By Holly Campbell  |    August 16, 2016
In case you missed it, a forthcoming study will disprove – once again – misleading claims pharmacy benefit managers and insurers, among others, routinely make about spending on new innovative...   Read More

Putting the cost of medicines in context

By Holly Campbell  |    August 4, 2016
Discussions about costs are important. No patient should have to worry about whether they can afford the care they need. At the same time, it is important to look at costs across the health care...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates